bioRxivMolecular BiologyPreprint
A noncanonical repressor function of JUN restrains YAP activity and suppresses YAP-dependent liver cancer growth
Yuliya V. Kurlishchuk, Anita Cindric Vranesic, Marco GründliD, Alexandra Kipping, KyungMok Kim, Paul Cramer, Björn von EyßiD
Abstract
Yes-associated protein (YAP) and its homologue, transcriptional coactivator with PDZ-binding motif (TAZ), are the main transcriptional downstream effector of the Hippo pathway. Decreased Hippo pathway activity leads to nuclear translocation of YAP/TAZ where they interact with TEAD transcription factors to induce target gene expression. Unrestrained YAP/TAZ activity can lead to excessive growth and tumor formation in a short time, underscoring the evolutionary need for tight control of these two transcriptional coactivators. The AP-1 complex binds together with YAP/TAZ to many common sites and they form a positive feed-forward to induce gene expression. Here, we report that the AP-1 component c-JUN acts as specific repressor of YAP/TAZ at joint target sites to decrease YAP/TAZ activity. This function of c-JUN is independent of its heterodimeric AP-1 partner c-FOS demonstrating that it is independent of the canonical AP-1 function to induce target gene expression. Since c-JUN is itself by YAP/TAZ, our work identifies a negative feedback loop that buffers YAP/TAZ activity at joint sites. This negative feedback loop needs to get disrupted in liver cancer to unlock the full oncogenic potential of YAP/TAZ. Our results thus demonstrate an additional layer of control for the important interplay of YAP/TAZ and AP-1.
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a potential therapeutic target in YAP/TAZ-active cancers
- The JNK and Hippo pathways control epithelial integrity and prevent tumour initiation by regulating an overlapping transcriptome
Katrina A. Mitchell, Joseph H.A. Vissers, … Kieran F. Harvey·bioRxiv·Jun 19, 2024
- The Hippo pathway effector YAP inhibits NF-kB signaling and ccRCC growth by opposing ZHX2
Xu Li, Yong Suk Cho, … Jin Jiang·Journal of Biological ChemistryPeer-reviewed·Mar 20, 2025
- MARK2/MARK3 kinases are catalytic co-dependencies of YAP/TAZ in human cancer
O. Klingbeil, D. Skopelitis, … C. R. Vakoc·bioRxiv·Feb 26, 2024
- Regulation of YAP activity by nuclear G-actin binding
Hong Wang, Irma M. Jayawardana, … Robert Grosse·Nucleic Acids ResearchPeer-reviewed·Mar 19, 2026
- Transient YAP/TAZ inhibition exposes therapeutic vulnerabilities in advanced cancers
Marco Jessen, KyungMok Kim, … Björn von Eyß·bioRxiv·Jul 3, 2025